0
Détail de l'éditeur
BioMed Central
Collections rattachées :
|
Documents disponibles chez cet éditeur (23)
Ajouter le résultat dans votre panier Affiner la recherche
Titre : Addiction to the nicotine gum in never smokers Type de document : texte imprimé Auteurs : Jean-François Etter, Auteur Editeur : BioMed Central Année de publication : 2007 Collection : BMC Public Health num. 7 Importance : 6 p. Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:constituant:alcaloïde:nicotine
[TABAC] étude
[TABAC] tabagisme:dépendance tabagique:dépendance pharmacologiqueIndex. décimale : TA 6.2.3.1.1 Chewing-gum Résumé : Background
Addiction to nicotine gum has never been described in never smokers or in never users of tobacco.
Methods
Internet questionnaire in 2004–2006 in a self-selected sample of 434 daily users of nicotine gum. To assess dependence on nicotine gum, we used modified versions of the Nicotine Dependence Syndrome Scale (NDSS), the Fagerström Test for Nicotine Dependence and the Cigarette Dependence Scale.
Results
Five never smokers used the nicotine gum daily. They had been using the nicotine gum for longer than the 429 ever smokers (median = 6 years vs 0.8 years, p = 0.004), and they had higher NDSS-gum Tolerance scores (median = 0.73 vs = -1.0, p = 0.03), a difference of 1.5 standard deviation units. Two never smokers had never used smokeless tobacco, both answered "extremely true" to: "I use nicotine gums because I am addicted to them", both "fully agreed" with: "after a few hours without chewing a nicotine gum, I feel an irresistible urge to chew one" and: "I am a prisoner of nicotine gum".
Conclusion
This is to our knowledge the first report of addiction to nicotine gum in never users of tobacco. However, this phenomenon is rare, and although the long-term effect of nicotine gum is unknown, this product is significantly less harmful than tobacco.En ligne : https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-7-159 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8139 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Analysis and evaluation of environmental tobacco smoke exposure as a risk factor for chronic cough / Beatrix Groneberg-Kloft (2007)
Titre : Analysis and evaluation of environmental tobacco smoke exposure as a risk factor for chronic cough Type de document : texte imprimé Auteurs : Beatrix Groneberg-Kloft, Auteur ; Wojciech Feleszko, Auteur ; Quoc Thai Dinh, Auteur ; Anke van Mark, Auteur Editeur : BioMed Central Année de publication : 2007 Collection : Cough, ISSN 1745-9974 num. 3 Importance : 6 p. Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] tabagisme:pathologie:pathologie respiratoire:broncho-pneumopathie chronique obstructive
[TABAC] tabagisme:tabagisme actif
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 7.4.2.2 chez l'adulte Résumé : Exposure to environmental tobacco smoke (ETS) and active tobacco smoking has been shown to increase symptoms of bronchial asthma such as bronchoconstriction but effects on other respiratory symptoms remain poorly assessed. Current levels of exposure to tobacco smoke may also be responsible for the development of chronic cough in both children and adults. The present study analyses the effects of tobacco smoke exposure as potential causes of chronic cough. A panel of PubMed-based searches was performed relating the symptom of cough to various forms of tobacco smoke exposure. It was found that especially prenatal and postnatal exposures to ETS have an important influence on children's respiratory health including the symptom of cough. These effects may be prevented if children and pregnant women are protected from exposure to ETS. Whereas the total number of studies adressing the relationship between cough and ETS exposure is relatively small, the present study demonstrated that there is a critical amout of data pointing to a causative role of environmental ETS exposure for the respiratory symptom of cough. Since research efforts have only targeted this effect to a minor extent, future epidemiological and experimental studies are needed to further unravel the relation between ETS and cough. En ligne : https://coughjournal.biomedcentral.com/articles/10.1186/1745-9974-3-6 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8058 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Breaking the habit : a qualitative exploration of barriers and facilitators to smoking cessation in people with enduring mental health problems Type de document : texte imprimé Auteurs : Susan Kerr, Auteur ; Charlotte Woods, Auteur ; Christina Knussen, Auteur ; Hazel Watson, Auteur ; Robert Hunter, Auteur Editeur : BioMed Central Année de publication : 12/03/2013 Collection : BMC Public Health num. 13:221 Importance : 9 p. Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:médecine:médecine spécialisée:psychiatrie
[TABAC] sevrage tabagiqueIndex. décimale : TA 6.3.5 Programmes de sevrage menés par les professionnels de santé Résumé : Background
Smoking in people with mental health problems (MHPs) is an important public health concern as rates are two to three times higher than in the general population. While a strong evidence base exists to encourage and support smoking cessation in the wider population, there is limited evidence to guide the tailoring of interventions for people with MHPs, including minimal understanding of their needs. This paper presents findings from theoretically-driven formative research which explored the barriers and facilitators to smoking cessation in people with MHPs. The aim, guided by the MRC Framework for the development and evaluation of complex interventions, was to gather evidence to inform the design and content of smoking cessation interventions for this client group.
Methods
Following a review of the empirical and theoretical literature, and taking a critical realist perspective, a qualitative approach was used to gather data from key stakeholders, including people with enduring MHPs (n = 27) and professionals who have regular contact with this client group (n = 54).
Results
There was a strong social norm for smoking in participants with MHPs and most were heavily addicted to nicotine. They acknowledged that their physical health would improve if they stopped smoking and their disposable income would increase; however, more important was the expectation that, if they attempted to stop smoking, their anxiety levels would increase, they would lose an important coping resource, they would have given up something they found pleasurable and, most importantly, their mental health would deteriorate. Barriers to smoking cessation therefore outweighed potential facilitators and, as a consequence, impacted negatively on levels of motivation and self-efficacy. The potential for professionals to encourage cessation attempts was apparent; however, they often failed to raise the issue of smoking/cessation as they believed it would damage their relationship with clients. The professionals’ own smoking status also appeared to influence their health promoting role.
Conclusions
Many opportunities to encourage and support smoking cessation in people with MHPs are currently missed. The increased understanding provided by our study findings and literature review have been used to shape recommendations for the content of tailored smoking cessation interventions for this client group.En ligne : https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-13-221 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7459 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Comparative risk perceptions of switching to JUUL vs. continued smoking and subsequent switching away from cigarettes / Arielle Seyla (2023)
Titre : Comparative risk perceptions of switching to JUUL vs. continued smoking and subsequent switching away from cigarettes : a longitudinal observational study Type de document : document électronique Auteurs : Arielle Seyla, Auteur ; Saul Shiffman, Auteur Editeur : BioMed Central Année de publication : 2023 Collection : BMC Psychology Importance : 14 p. Présentation : tab., graph Langues : Anglais (eng) Catégories : [TABAC] CANDIDATS:e-cigarette
[TABAC] chimie du tabac:constituant:alcaloïde:nicotine
[TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique
[TABAC] tabagisme:risqueMots-clés : juul Index. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Background
Evidence indicates that electronic nicotine delivery systems (ENDS) pose lower risk than cigarettes; however, many smokers harbor misperceptions that ENDS are equally or more harmful, possibly deterring them from switching. This study examines whether comparative risk perceptions of JUUL vs. smoking are associated with subsequent switching, among smokers who recently purchased JUUL.
Methods
N = 16,996 current established smokers who recently purchased a JUUL Starter Kit were followed 6 times over 12 months. Comparative risk perceptions were assessed using both direct and indirect measures (i.e., contrasting JUUL and smoking directly in questions, and deriving from separate absolute scales). Repeated-measures logistic regression examined switching across follow-up (no smoking in past 30 days) as a function of baseline risk perceptions, adjusting for demographics and baseline smoking behavior.
Results
Perceiving JUUL as less harmful than smoking was associated with higher switching rates, using both direct (e.g., adjusted odds ratio [AOR] = 1.48 for “JUUL much less” vs. “more/much more harmful”) and indirect (AOR = 1.07, for each 10-unit increase in fraction; AOR = 1.51 for highest (6-100) vs. lowest (0 to < 1) fraction categories) comparative risk measures (all p < 0.0001). Among the subset smoking 10 + cigarettes per day, associations between risk perceptions and switching were more pronounced (AOR = 2.51 for “JUUL much less” vs. “more/much more harmful”;
AOR = 1.81 for 6-100 vs. 0 to < 1 fraction, both p < 0.0001).
Conclusions
Smokers who perceive JUUL as less harmful than cigarettes have higher odds of switching. Future research should examine whether messaging which aligns comparative risk perceptions with current evidence can facilitate switching, especially among heavier smokers.En ligne : https://doi.org/10.1186/s40359-023-01351-8 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10261 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Do sociodemographic risk profiles for adolescents engaging in weekly e-cigarette, cigarette, and dual product use differ? Type de document : document électronique Auteurs : Katelyn Battista, Auteur ; Karen A Patte, Auteur ; Terrance Wade, Auteur Editeur : BioMed Central Année de publication : 2024 Collection : BMC Public Health num. 24(1558) Importance : p. 1-11 Présentation : tab.; ill. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Canada
[DIVERS] personne:famille:adolescent
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:enquête
[TABAC] étude:épidémiologie:milieu socio-économique
[TABAC] tabagisme:risque
[TABAC] tabagisme:tabagisme actifIndex. décimale : TA 2.4.3.4 Étudiants Résumé : Background
E-cigarette use represents a contemporary mode of nicotine product use that may be changing the risk profile of participating adolescents. Understanding diferences in sociodemographic characteristics of adolescents engaging in contemporary e-cigarette use and traditional cigarette use is important for efectively developing and targeting public health intervention programs. The objective of this study was to identify and compare sociode‑ mographic risk profles for exclusive e-cigarette use and dual-product use among a large sample of Canadian youth.
Methods
A survey of 46,666 secondary school students in the 2021-22 wave of the COMPASS study measured fre‑ quency of past month e-cigarette and cigarette use as well as age, sex, gender, racial or ethnic background, spending money, relative family afuence, and having one’s own bedroom. Rates of cigarette-only, e-cigarette-only, and dual product use were calculated, and separate classifcation trees were run using the CART algorithm to identify sociode‑ mographic risk profles for weekly dual-product use and weekly e-cigarette-only use.
Results
Over 13% of adolescents used only e-cigarettes at least weekly, 3% engaged in weekly dual e-cigarette and cigarette use, and less than 0.5% used only cigarettes. Available spending money was a common predictor of dual-product and e-cigarette-only use. Gender diverse youth and youth with lower perceived family afuence were at higher risk for dual-product use, while white and multiethnic adolescents were at greater risk of e-cigarette-only use. Two high-risk profles were identifed for e-cigarette-only use and four high-risk profles were identifed for dual product use.
Conclusions
This study used a novel modelling approach (CART) to identify combinations of sociodemographic characteristics that profle high-risk groups for exclusive e-cigarette and dual-product use. Unique risk profles were identifed, suggesting that e-cigarettes are attracting new demographics of adolescents who have not previously been considered as high-risk for traditional cigarette use.
En ligne : https://doi.org/10.1186/s12889-024-18813-2 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10518 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Do students develop better motivational interviewing skills through role-play with standardised patients or with student colleagues? Type de document : texte imprimé Auteurs : Anne L. Mounsey, Auteur Editeur : BioMed Central Année de publication : 2006 Collection : Medical Education num. 40 Importance : 775-780 Langues : Anglais (eng) Catégories : [DIVERS] personne:famille:adolescent
[DIVERS] personne:par âge:jeune
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:entretien motivationnelIndex. décimale : TA 6.2.2 Approche psychologique (y compris entretien motivationnel) Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2596 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001438 TA 6.2.2 MOU D Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of e-cigarettes as a stop smoking intervention in adults : a systematic review Type de document : document électronique Auteurs : Niyati Vyas, Auteur ; Alexandria Bennet, Auteur ; Candyce Hamel, Auteur Editeur : BioMed Central Année de publication : 2024 Collection : BMC Medicine, ISSN 1741-7015 num. 13(168) Importance : p. 1-16 Présentation : ill. Langues : Anglais (eng) Catégories : [DIVERS] personne:par âge:adulte
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude
[TABAC] sevrage tabagique
[TABAC] tabagisme:risqueIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Background
This systematic review aims to identify the benefts and harms of electronic cigarettes (e-cigarettes) as a smoking cessation aid in adults (aged≥18 years) and to inform the development of the Canadian Task Force on Preventive Health Care’s (CTFPHC) clinical practice guidelines on e-cigarettes.
Methods
We searched Ovid MEDLINE®, Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Cita tions, PsycINFO, Embase Classic+Embase, and the Cochrane Library on Wiley. Searches were conducted from January 2016 to July 2019 and updated on 24 September 2020 and 25 January 2024. Two reviewers independently performed title-abstract and full-text screening according to the pre-determined inclusion criteria. Data extraction, quality assess ments, and the application of Grading of Recommendations Assessment, Development and Evaluation (GRADE) were performed by one independent reviewer and verifed by another.
Results
We identifed 18 studies on 17 randomized controlled trials that compared e-cigarettes with nicotine to e-cigarettes without nicotine and e-cigarettes (with or without nicotine) to other interventions (i.e., no interven tion, waitlist, standard/usual care, quit advice, or behavioral support). Considering the benefts of e-cigarettes in terms of smoking abstinence and smoking frequency reduction, 14 studies showed small or moderate benefts of e-ciga rettes with or without nicotine compared to other interventions; although, with low, very low or moderate evidence certainty. With a focus on e-cigarettes with nicotine specifcally, 12 studies showed benefts in terms of smoking abstinence when compared with usual care or non-nicotine e-cigarettes. In terms of harms following nicotine or non nicotine e-cigarette use, 15 studies reported mild adverse events with little to no diference between groups and low to very low evidence certainty.
Conclusion
The evidence synthesis on the e-cigarette’s efectiveness shows data surrounding benefts having low to moderate evidence certainty for some comparisons and very low certainty for others, indicating that e-cigarettes may or probably increase smoking cessation, whereas, for harms, there is low to very low evidence certainty. Since the duration for outcome measurement varied among diferent studies, it may not be long-term enough for Adverse Events (AEs) to emerge, and there is a need for more research to understand the long-term benefts and potential harms of e-cigarettes.
En ligne : https://doi.org/10.1186/s13643-024-02572-7 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10507 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of nicotine salt vapes, cytisine, and a combination of these products, for smoking cessation in New Zealand : protocol for a three‑arm, pragmatic, community‑based randomised controlled trial Type de document : document électronique Auteurs : Natalie Walker, Auteur ; Amanda Calder, Auteur ; Joanne Barnes, Auteur Editeur : BioMed Central Année de publication : 2023 Collection : BMC Public Health Importance : 11 p. Présentation : ill., tab. Langues : Anglais (eng) Catégories : [TABAC] CANDIDATS:e-cigarette
[TABAC] chimie du tabac:constituant:alcaloïde:nicotine
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[DIVERS] géographie:Océanie:Nouvelle-ZélandeIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Background
Combining short-acting nicotine replacement therapy with varenicline increases smoking cessation rates compared with varenicline alone, but not all people tolerate these medications or find them helpful. We aim to investigate the therapeutic potential of an analogous combination, by evaluating the effectiveness, safety, and acceptability of combining nicotine salt e-cigarettes with cytisine, compared to nicotine salt e-cigarettes or cytisine only, on smoking abstinence at six months.
Methods
A pragmatic, community-based, investigator-blinded, randomised superiority trial design will be utilised. Eligible participants will be people who smoke daily (N = 800, 90% power) from throughout New Zealand, who are: aged ≥ 18 years, motivated to quit in the next two weeks, able to provide online consent, willing to use e-cigarettes and/or cytisine, and have daily access to a mobile phone. Recruitment will utilise multi-media advertising. Participants will be randomised (3:3:2 ratio) to 12 weeks of: 1) e-cigarettes (closed pod system, 3% nicotine salt, tobacco flavour)
plus cytisine; 2) e-cigarettes alone, or 3) cytisine alone. All groups will receive a six-month, text-message-based behavioural support programme. The primary outcome is self-reported, biochemically verified, continuous abstinence at six months post-quit date. Secondary outcomes, measured at quit date, then one, three, six, and 12 months post-quit date, include self-reported continuous abstinence, 7-day point prevalence abstinence, cigarettes smoked per day, withdrawal and urge to smoke, time to (re)lapse, treatment use and compliance, treatment crossover, dual-use, use of other cessation products, change in e-cigarette products, continuation of product use, acceptability, change in health state, health-related quality of life, change in body mass index, adverse events, and cost per quitter.
Discussion
Pragmatic trials are of particular value as they reflect the ‘real world’ impact of interventions. The trial will provide some of the first evidence on the effectiveness of combining nicotine salt e-cigarettes with cytisine for smoking cessation, in a country with strong tobacco control policy. Findings will be incorporated into relevant systematic reviews, informing practice and policy.En ligne : https://doi.org/10.1186/s12889-023-16665-w Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10264 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of smoking cessation therapies : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Ping Wu, Auteur ; Kumanan Wilson, Auteur ; Popey Dimoulas, Auteur Editeur : BioMed Central Année de publication : 2006 Collection : BMC Public Health num. Vol. 6 Importance : 16 p. Présentation : tab., ill. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : BACKGROUND:
Smoking remains the leading preventable cause of premature deaths. Several pharmacological interventions now exist to aid smokers in cessation. These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis.
METHODS:
We searched 10 electronic medical databases (inception to Sept. 2006) and bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating interventions for smoking cessation at 1 year, through chemical confirmation. Our primary endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking cessation (approximately 3 months) and adverse events. We conducted random-effects meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and when these did not exist, we calculated indirect comparisons.
RESULTS:
We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95% Confidence Interval [CI], 1.55-1.88, P =< 0.0001). This was consistent when examining all placebo-controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60-1.99), NRT gum (OR 1.60, 95% CI, 1.37-1.86) or patch (OR 1.63, 95% CI, 1.41-1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI, 1.77-2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10-2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72-2.64). Two RCTs evaluated the superiority of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20-6.42). Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12-4.12, P =< 0.0001) and also at approximately 3 months (OR 3.75, 95% CI, 2.65-5.30). Three RCTs evaluated the effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22-2.05) and at approximately 3 months (OR 1.61, 95% CI, 1.16-2.21). Using indirect comparisons, varenicline was superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17-2.36, P = 0.004) or to all controls at 1 year (OR 1.73, 95% CI 1.22-2.45, P = 0.001). This was also the case for 3-month data. Adverse events were not systematically different across studies.
CONCLUSION:
NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness.En ligne : https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-6-300 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7965 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of stop smoking interventions among adults : an overview of systematic reviews Type de document : document électronique Auteurs : Mona Hersi, Auteur ; Andrew Beck, Auteur ; Candyce Hamel, Auteur Editeur : BioMed Central Année de publication : 2023 Collection : BMC Medicine, ISSN 1741-7015 num. 8(1) Importance : 21 p. Présentation : ill., tab. Langues : Anglais (eng) Catégories : [DIVERS] personne:par âge:adulte
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:effet du sevrage:bénéfice du sevrage tabagique
[TABAC] tabagisme:risqueIndex. décimale : TA 6.10 Conséquences / effets à long-terme du sevrage Résumé : Background: Tobacco smoking is the leading cause of cancer, preventable death, and disability. Smoking cessation can increase life expectancy by nearly a decade if achieved in the third or fourth decades of life. Various stop smoking interventions are available including pharmacotherapies, electronic cigarettes, behavioural support, and alternative therapies. This protocol outlines an evidence review which will evaluate the benefits and harms of stop smoking interventions in adults.
Methods: The evidence review will consist of two stages. First, an overview of systematic reviews evaluating the benefits and harms of various stop smoking interventions delivered in or referred from the primary care setting will be conducted. The second stage will involve updating a systematic review on electronic cigarettes identified in the overview; randomized controlled trials will be considered for outcomes relating to benefits while randomized controlled trials, non-randomized controlled trials, and comparative observational studies will be considered for evaluating harms. Search strategies will be developed and peer-reviewed by medical information specialists. The search strategy for the updated review on e-cigarettes will be developed using that of the candidate systematic review. The MEDLINE®, PsycINFO, Embase, and the Cochrane Library electronic databases will be searched as of 2008 for the overview of reviews and from the last search date of the selected review for the updated review. Organizational websites and trial registries will be searched for unpublished or ongoing reviews/studies. Two reviewers will independently screen the title and abstracts of citations using the liberal accelerated method. Full-text screening will be performed independently by two reviewers. Extracted data will be verified by a second reviewer. Disagreements regarding full-text screening and data extraction will be resolved by consensus or third-party adjudication. The methodological quality of systematic reviews, risk of bias of randomized and non-randomized trials, and methodological quality of cohort studies will be evaluated using AMSTAR 2, the Cochrane risk of bias tool, and a modified version of the Scottish Intercollegiate Guidelines Network critical appraisal tool, respectively. The GRADE framework will be used to assess the quality of the evidence for outcomes.
Discussion: The evidence review will evaluate the benefits and harms of various stop smoking interventions for adults. Findings will be used to inform a national tobacco cessation guideline by the Canadian Task Force on Preventive Health Care.En ligne : https://doi.org/10.1186/s13643-018-0928-x Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10575 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Electronic cigarettes : a survey of users Type de document : texte imprimé Auteurs : Jean-François Etter, Auteur Editeur : BioMed Central Année de publication : 2010 Importance : 18 p. Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique Index. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) En ligne : https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-10-231 Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2278 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Feasibility of restricting e-cigarettes to prescription only for smoking cessation Type de document : document électronique Auteurs : Katya Peri, Auteur ; M.J. Eisenberg, Auteur Editeur : BioMed Central Année de publication : 2024 Collection : Respiratory Research num. 25 Importance : 4 p. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Canada
[DIVERS] géographie:Océanie:Australie
[DIVERS] personne:par âge:jeune
[TABAC] CANDIDATS:e-cigarette
[TABAC] sevrage tabagique:aide au sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:prescriptionIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : E-cigarette use among youth in Canada has risen to epidemic proportions. E-cigarettes are also moderately useful smoking cessations aids. Restricting e-cigarettes to prescription only smoking cessation aids could help limit youth’s access to them while keeping them available as therapies for patients who smoke conventional cigarettes.
In Canada, drugs or devices must be approved by regulatory bodies such as Health Canada in order to become licensed prescription medications. A similar situation is underway in Australia, where e-cigarettes have been restricted to prescription only. This commentary explores the feasibility of a similar regulation for e-cigarettes in Canada as prescription smoking cessation aids.En ligne : https://doi.org/10.1186/s12931-024-02792-4 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10293 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Group hypnosis vs. relaxation for smoking cessation in adults : a cluster-randomised controlled trial Type de document : document électronique Auteurs : Maria Dickson-Spillmann, Auteur ; Severin Haug, Auteur ; Michael P Schaub, Auteur Editeur : BioMed Central Année de publication : 2013 Collection : BMC Public Health num. 13 Importance : p.1227-1235 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe occidentale:Suisse
[DIVERS] personne:par âge:adulte
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode collective:groupe
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:hypnose
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:relaxation (méthode)Index. décimale : TA 6.2.5.3 Hypnose, relaxation et sophrologie Résumé : Background:
Despite the popularity of hypnotherapy for smoking cessation, the efficacy of this method is unclear. We aimed to investigate the efficacy of a single-session of group hypnotherapy for smoking cessation compared to relaxation in Swiss adult smokers.
Methods:
This was a cluster-randomised, parallel-group, controlled trial. A single session of hypnosis or relaxation for smoking cessation was delivered to groups of smokers (median size = 11). Participants were 223 smokers consuming ≥ 5 cigarettes per day, willing to quit and not using cessation aids (47.1% females, M = 37.5 years
[SD = 11.8], 86.1% Swiss). Nicotine withdrawal, smoking abstinence self-efficacy, and adverse reactions were assessed at a 2-week follow-up. The main outcome, self-reported 30-day point prevalence of smoking abstinence, was assessed at a 6-month follow up. Abstinence was validated through salivary analysis. Secondary outcomes included number of cigarettes smoked per day, smoking abstinence self-efficacy, and nicotine withdrawal.
Results:
At the 6-month follow up, 14.7% in the hypnosis group and 17.8% in the relaxation group were abstinent. The intervention had no effect on smoking status (p = .73) or on the number of cigarettes smoked per day (p = .56). Smoking abstinence self-efficacy did not differ between the interventions (p = .14) at the 2-week follow-up, but non-smokers in the hypnosis group experienced reduced withdrawal (p = .02). Both interventions produced few adverse reactions (p = .81).
Conclusions:
A single session of group hypnotherapy does not appear to be more effective for smoking cessation than a group relaxation session.En ligne : https://doi.org/10.1186/1471-2458-13-1227 Format de la ressource électronique : Page de l'éditeur Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9570 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? : a randomised controlled trial Type de document : texte imprimé Auteurs : Peter Hajek, Auteur ; Katie Myers Smith, Auteur ; Al-Rehan Dhanji, Auteur ; Hayden McRobbie, Auteur Editeur : BioMed Central Année de publication : 2013 Collection : BMC Medicine, ISSN 1741-7015 Importance : p. 7 Langues : Français (fre) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Background
Nicotine replacement therapy (NRT) and varenicline are both effective in helping smokers quit. There is growing interest in combining the two treatments to improve treatment outcomes, but no experimental data exist on whether this is efficacious. This double-blind randomised controlled trial was designed to evaluate whether adding nicotine patches to varenicline improves withdrawal relief and short-term abstinence rates.
Methods
117 participants seeking help to stop smoking were randomly allocated to varenicline plus placebo patch or varenicline plus nicotine patch (15 mg/16 hour). Varenicline use commenced one week prior to the target quit date (TQD), patch use started on the TQD. Ratings of urges to smoke and cigarette withdrawal symptoms were collected weekly over 4 weeks post-TQD. Medication use and smoking status were established at 1, 4 and 12 weeks. Participants lost to follow-up were included as continuing smokers.
Results
92% of participants used both medications during the first week after the TQD. The combination treatment generated no increase in nausea or other adverse effects. It had no overall effect on urges to smoke or on other withdrawal symptoms. The combination treatment did not improve biochemically validated abstinence rates at 1 week and 4 weeks post-TQD (69% vs 59%, p=0.28 and 60% vs 59%, p=0.91, in the nicotine patch and placebo patch arm, respectively), or self reported abstinence rates at 12 weeks (36% vs. 29%, p=0.39, NS).
Conclusions
The efficacy of varenicline was not enhanced by the addition of nicotine patches, although further trials would be useful to exclude the possibility of type II error.En ligne : https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-140 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7445 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A randomized controlled trial of smartphone-based mindfulness training for smoking cessation : a study protocol Type de document : texte imprimé Auteurs : Kathleen A. Garrison, Auteur ; Prasanta Pal, Auteur ; Rahil Rojiani, Auteur Editeur : BioMed Central Année de publication : 2015 Collection : BMC Psychiatry, ISSN 1471-244X num. 15 (83) Importance : 7 p. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique
[TABAC] sevrage tabagique:aide au sevrage:service d'aide
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:mindfulnessRésumé : Le tabagisme est responsable de la mort d'environ un individu sur dix dans le monde. La formation à la pleine conscience a montré une efficacité préliminaire en tant que traitement comportemental pour l'arrêt du tabagisme. De récentes avancées dans le domaine de la santé mobile suggèrent les avantages d'un traitement de sevrage tabagique basé sur le smartphone, notamment la formation à la pleine conscience. Cette étude évalue l'efficacité d'un programme de formation à la pleine conscience basé sur une application pour smartphone pour améliorer le taux d'abandon du tabac après un suivi de six mois.
En ligne : https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-015-0468-z Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9108 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
